Selected article for: "human immunodeficiency and respiratory syndrome"
Author: Liao, Pei-Yu; Choi, Yong Seok; Dinman, Jonathan D.; Lee, Kelvin H.
Title: The many paths to frameshifting: kinetic modelling and analysis of the effects of different elongation steps on programmed –1 ribosomal frameshifting
  • Document date: 2010_9_7
    • ID: wwq0sd2r_1
    Snippet: Programmed ribosomal frameshifting (PRF) is a process where specific signals in the mRNA direct the ribosome to switch reading frame at a certain efficiency. In À1 PRF, the ribosome slips 1 nt towards the 5 0 -end of the mRNA during translation. Several viruses, including human immunodeficiency virus type 1 (HIV-1) and the coronavirus responsible for severe acute respiratory syndrome (SARS-CoV), employ À1 PRF to synthesize precursors of enzymes.....
    Document: Programmed ribosomal frameshifting (PRF) is a process where specific signals in the mRNA direct the ribosome to switch reading frame at a certain efficiency. In À1 PRF, the ribosome slips 1 nt towards the 5 0 -end of the mRNA during translation. Several viruses, including human immunodeficiency virus type 1 (HIV-1) and the coronavirus responsible for severe acute respiratory syndrome (SARS-CoV), employ À1 PRF to synthesize precursors of enzymes for their replication (1, 2) , and the ratio of the zero frame to À1 frame encoded products is important to the vitality of viruses (3) (4) (5) . As such, altering À1 PRF efficiency may damage viral replication [reviewed in (6) ]. This suggests À1 PRF as a target for the development of antiviral therapeutics.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and antiviral therapeutic development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and antiviral therapeutic development target: 1, 2
    • acute respiratory syndrome and certain efficiency: 1
    • acute respiratory syndrome and enzyme precursor: 1
    • acute respiratory syndrome and human immunodeficiency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and PRF efficiency: 1, 2, 3
    • acute respiratory syndrome and PRF ribosomal frameshifting: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and reading frame: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral therapeutic and certain efficiency: 1
    • antiviral therapeutic and human immunodeficiency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • antiviral therapeutic and PRF efficiency: 1
    • antiviral therapeutic and PRF ribosomal frameshifting: 1
    • antiviral therapeutic and reading frame: 1, 2, 3
    • antiviral therapeutic and respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral therapeutic development and PRF efficiency: 1
    • antiviral therapeutic development and PRF ribosomal frameshifting: 1
    • antiviral therapeutic development and reading frame: 1, 2
    • antiviral therapeutic development and respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13